Education
About Us
Working with TipRanks
Follow Us
Pulse Biosciences (PLSE)
NASDAQ:PLSE
Top Page
Pulse Biosciences
(NASDAQ:PLSE)
44Neutral
Pulse Biosciences (PLSE) vs. S&P 500 (SPY)
Market Cap
$1.16B
Dividend YieldN/A
Average Volume (3M)171.79K
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue GrowthN/A
EPS Growth-1.00%
CountryUS
Employees75
SectorHealthcare
Sector Strength41
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.17
Shares Outstanding67,273,865
10 Day Avg. Volume167,691
30 Day Avg. Volume171,791
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)8.68
Price to Sales (P/S)0.00
P/FCF Ratio-31.49
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue171.72
Enterprise Value/Gross Profit-1.25K
Enterprise Value/Ebitda-5.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pulse Biosciences Business Overview & Revenue Model
Company DescriptionPulse Biosciences, Inc. is a medical technology company that focuses on developing and commercializing innovative therapeutic treatments leveraging its proprietary Nano-Pulse Stimulation (NPS) technology. Operating within the healthcare and medical device sectors, Pulse Biosciences aims to provide non-thermal, cellular-specific treatments for a range of dermatological and oncological conditions. The company's core product, the CellFX System, is designed to deliver precise energy pulses to treat benign and malignant lesions on the skin.
How the Company Makes MoneyPulse Biosciences generates revenue primarily through the sale and leasing of its CellFX System to dermatologists and other healthcare providers. The company may also earn revenue from service agreements, training, and support services related to the use of its systems. Additionally, Pulse Biosciences could engage in strategic partnerships or collaborations with other healthcare organizations to further expand the application of its technology and enhance its market presence. Key factors contributing to its earnings include the adoption and integration of its technology within clinical practices and potential expansion into international markets.
Pulse Biosciences Financial Statement Overview
Summary
Pulse Biosciences faces significant financial challenges, marked by persistent losses, lack of revenue growth, and high cash burn. The financial health is buoyed by equity financing, yet this raises sustainability concerns without a clear path to operational profitability. Strategic adjustments are essential to improve revenue generation and operational efficiency, ensuring long-term viability.Income Statement
Pulse Biosciences has consistently struggled with profitability, as evidenced by negative net income and EBIT across all years. The absence of revenue in recent years highlights significant challenges in achieving market penetration and product adoption. The net profit margin is negative due to sustained losses, indicating a need for strategic pivots or operational improvements. The company has not shown revenue growth, which is critical for future viability.20
Very Negative
Balance Sheet
The balance sheet shows a relatively strong equity position with stockholders' equity increasing over recent years, supported by substantial financing inflows. The company maintains a low debt-to-equity ratio, indicating lower financial leverage and potential for future borrowing if needed. However, the negative equity in 2022 and fluctuating asset base reflect operational instability. The equity ratio has been volatile, reflecting the financial restructuring efforts undertaken by the company.30
Negative
Cash Flow
The cash flow statement indicates persistent negative operating cash flow, which is a critical concern for sustainability. Although there has been substantial financing inflow, this is primarily used to cover operational deficits. There is no positive free cash flow growth, and the free cash flow to net income ratio reflects ongoing cash burn. Operating cash flow to net income is negative, indicating inefficiencies in cash generation from core activities.25
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 700.00K | 1.42M | 0.00 | Gross Profit |
| 0.00 | -1.21M | -11.24M | -550.00K | -665.00K | EBIT |
| -56.26M | -43.57M | -58.06M | -63.01M | -49.97M | EBITDA |
| -52.41M | -42.37M | -56.70M | -61.87M | -48.87M | Net Income Common Stockholders |
| -53.59M | -42.21M | -58.95M | -63.16M | -49.74M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 118.04M | 44.37M | 61.14M | 28.61M | 20.48M | Total Assets |
| 132.46M | 59.15M | 77.88M | 54.25M | 41.29M | Total Debt |
| 8.90M | 9.14M | 75.96M | 11.25M | 11.36M | Net Debt |
| -109.14M | -35.22M | 14.82M | -17.36M | -1.11M | Total Liabilities |
| 17.60M | 14.79M | 80.13M | 18.56M | 18.40M | Stockholders Equity |
| 114.86M | 44.36M | -2.25M | 35.69M | 22.89M |
| Cash Flow | Free Cash Flow | |||
| -36.47M | -33.16M | -47.41M | -54.53M | -35.81M | Operating Cash Flow |
| -36.34M | -33.04M | -47.01M | -54.10M | -35.37M | Investing Cash Flow |
| -125.00K | -121.00K | -401.00K | 7.56M | 10.04M | Financing Cash Flow |
| 110.14M | 16.39M | 79.94M | 62.69M | 30.89M |
Pulse Biosciences Technical Analysis
Positive
17.19
Price Trends
16.65
Positive
17.97
Negative
17.80
Negative
Market Momentum
-0.06
Positive
52.43
Neutral
42.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLSE, the sentiment is Positive. The current price of 17.19 is below the 20-day moving average (MA) of 17.27, above the 50-day MA of 16.65, and below the 200-day MA of 17.80, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 52.43 is Neutral, neither overbought nor oversold. The STOCH value of 42.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PLSE.
Pulse Biosciences Risk Analysis
Pulse Biosciences disclosed 61 risk factors in its most recent earnings report. Pulse Biosciences reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pulse Biosciences Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $178.98M | 14.52 | 10.59% | 2.20% | -19.92% | ― | |
54 Neutral | $1.12B | ― | -3.29% | ― | -23.12% | 97.46% | |
52 Neutral | $5.15B | 3.02 | -44.64% | 2.82% | 16.45% | -0.47% | |
52 Neutral | $181.76M | 25.27 | -7.77% | ― | -46.95% | -237.44% | |
52 Neutral | $951.89M | 55.81 | -19.14% | ― | -14.44% | -557.38% | |
44 Neutral | $1.16B | ― | -77.86% | ― | ― | -1.00% | |
34 Underperform | $1.26B | ― | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
PLSE
Pulse Biosciences
17.19
8.61
100.35%
OSUR
Orasure Technologies
2.43
-2.50
-50.71%
STAA
Staar Surgical
19.22
-23.58
-55.09%
UTMD
Utah Medical Products
55.10
-12.48
-18.47%
BLFS
BioLife Solutions
23.59
1.76
8.06%
KMTS
Kestra Medical Technologies Ltd.
24.62
3.63
17.29%
Pulse Biosciences Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: 2.02%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call highlights significant advancements in clinical trials, FDA approvals, and cash position, indicating robust progress in technology and market penetration. However, the increased operating expenses and cash usage present challenges that need addressing.Q1-2025 Updates
Positive Updates
FDA Clearances and Breakthrough Device Designation
Pulse Biosciences has obtained seven FDA clearances and received a breakthrough device designation for their cardiac surgical clamp, indicating strong validation of their technology.
Successful Clinical Trials
Clinical trials for the nsPFA 360 catheter demonstrated excellent procedure efficiency and acute outcomes, with 130 AF patients treated in European clinical feasibility studies.
Positive Outcomes for Thyroid Nodule Treatment
The nsPFA percutaneous electrode achieved an average 83% volume reduction in thyroid nodules at one year, with significant symptom reductions one month post-treatment.
Increased Cash Position
The company raised $14 million through the exercise of warrants, increasing cash and cash equivalents to $119.3 million as of March 31, 2025.
Encouraging Cardiac Catheter System Results
The 360 cardiac catheter system showed a 94.2% success rate for pulmonary vein isolation and a 95.5% success rate for left atrial posterior wall isolation.
Negative Updates
Increased Operating Expenses
Total GAAP costs and expenses increased by $7.4 million to $18 million, primarily due to higher noncash stock-based compensation and other administrative expenses.
Higher Cash Usage
Cash used in operating activities during Q1 2025 was $13.5 million, up from $9.8 million in the same period the previous year.
Company Guidance
During the Pulse Biosciences First Quarter 2025 Financial Results Conference Call, CEO Paul LaViolette highlighted the company's strategic focus on advancing Nanosecond Pulsed Field Ablation (nsPFA) technology and its applications across various medical fields. The company achieved significant milestones, such as treating over 6,000 patients and obtaining FDA breakthrough device designation for its cardiac surgical clamp. Priorities for 2025 include the commercialization of a percutaneous electrode for soft tissue ablation in benign thyroid disease and initiating IDE pivotal studies for their Cardiac 360 catheter and cardiac surgical clamp. Financially, Pulse Biosciences reported a GAAP net loss of $16.8 million for Q1 2025, with cash and cash equivalents totaling $119.3 million as of March 31, 2025. The company raised $14 million through warrant exercises, maintaining its cash position similar to year-end 2024. These developments reflect the company's commitment to transforming patient care through innovative therapies.Pulse Biosciences Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Pulse Biosciences Strengthens Leadership with New CFO Appointment
Positive
Feb 4, 2025
Pulse Biosciences announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025, to bolster its executive team as it scales the commercialization of its CellFX nanosecond PFA platform. Skinner, with extensive experience in financial leadership across healthcare and industrial sectors, brings strategic insights that are expected to aid in advancing Pulse Biosciences’ operational excellence and market positioning.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.